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Development
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Abstract
Background: Recent observational research indicates that immune development may be programmed by
nutritional exposures early in life. Such findings require replication from trials specifically designed to assess the
impact of nutritional intervention during pregnancy on infant immune development. The current trial seeks to
establish: (a) which combination of protein-energy (PE) and multiple-micronutrient (MMN) supplements would be
most effective; and (b) the most critical periods for intervention in pregnancy and infancy, for optimal immune
development in infancy.
Methods/Design: The ENID Trial is a 2 x 2 x 2 factorial randomized, partially blind trial to assess whether nutritional
supplementation to pregnant women (from < 20 weeks gestation to term) and their infants (from 6 to 12 months
of age) can enhance infant immune development. Eligible pregnant women from the West Kiang region of The
Gambia (pregnancy dated by ultrasound examination) are randomized on entry to 4 intervention groups (Iron-
folate (FeFol = standard care), multiple micronutrients (MMN), protein-energy (PE), PE + MMN). Women are visited at
home weekly for supplement administration and morbidity assessment and seen at MRC Keneba at 20 and
30 weeks gestation for a detailed antenatal examination, including ultrasound. At delivery, cord blood and placental
samples are collected, with detailed infant anthropometry collected within 72 hours. Infants are visited weekly
thereafter for a morbidity questionnaire. From 6 to 12 months of age, infants are further randomized to a
lipid-based nutritional supplement, with or without additional MMN. The primary outcome measures of this study
are thymic development during infancy, and antibody response to vaccination. Measures of cellular markers of
immunity will be made in a selected sub-cohort. Subsidiary studies to the main trial will additionally assess the
impact of supplementation on infant growth and development to 24 months of age.
Discussion: The proposed trial is designed to test whether nutritional repletion can enhance early immune
development and, if so, to help determine the most efficacious form of nutritional support. Where there is evidence
of benefit from a specific intervention/combination of interventions, future research should focus on refining the
supplements to achieve the optimal, most cost-effective balance of interventions for improved health outcomes.
Trial registration: ISRCTN49285450
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Background
General evidence for nutritional programming of
immunity
A substantive and continually expanding body of obser-
vational evidence supports the thesis that nutritional
exposures during pregnancy and/or early infancy may
programme developing organ systems and homeostatic
pathways, with later consequences for disease outcomes –
the ‘Developmental Origins of Health and Disease’
hypothesis (DOHaD) [1]. Whilst most research to
date within this field has focused on programming of
chronic degenerative disease, evidence also exists to
suggest that the developing immune system may be
particularly vulnerable to early-life insults from nutri-
tional inadequacies [2]. Such defects would result in
later life deficiencies in immuno-competence and suscep-
tibility to morbidity and mortality from infectious disease.
In rural Gambia, many aspects of health and behaviour
are defined by the distinct seasonal pattern, with a long
dry season from November to June followed by a period
of intense rainfall lasting from July to October. Pregnant
women are especially susceptible to these effects, with
seasonal patterns observed in pregnancy weight gains
[3], length of gestation [4] and birth weight [5]. We have
previously observed that, in this community, birth sea-
son predicts infection-related mortality, providing evi-
dence that seasonal factors in early life may programme
immune development [6,7]. Data from prospective birth
cohort studies in The Gambia [8] and Bangladesh [9]
demonstrate environmental effects on thymic size and,
in The Gambia, on markers of cellular immunity [10,11].
Cohort studies in adolescents and adults from Philippines
[12] and Pakistan [13,14] respectively link early life
nutritional exposures to possible long term defects in
functional immunity, as assessed by antibody response to
vaccination.
To date, however, the majority of the published
research in this area from our group and others has
focused on observational studies designed to unravel the
biological mechanisms underpinning early-life program-
ming of immune function. Rather than continue with
such studies within this field, we have initiated a proof-
of-principle intervention trial employing comprehensive
multiple micronutrient (MMN) and protein-energy (PE)
supplements to both mother during pregnancy and her
infant from six-months of age in The Gambia. The re-
cent development of affordable lipid-based nutritional
supplements (LNS) allows a direct comparison between
different routes of MMN administration. To date, LNS
have widely been used successfully in the treatment of
malnutrition and a wider research agenda is currently
looking at the use of LNS for the prevention of malnu-
trition. LNS outperforms other forms of MMN supple-
mentation in terms of growth; in a recent trial in Ghana,
3 types of micronutrient supplements for home fortifica-
tion of complementary foods were compared [15]. The
most effective supplement was found to be an energy-
dense peanut-based fortified spread ‘Nutributter’ [16].
Additional advantages of LNS favouring translational
applications include local production, long shelf life and
safety.
The aim of the current trial is to test the hypothesis
that early-life immunocompetence can be enhanced by a
‘life-course’ approach involving LNS to achieve nutri-
tional repletion in late gestation and infancy, with conse-
quent benefits in reducing vaccine failures and morbidity,
and enhancing growth. The proposed design will specific-
ally be able to test three exposures: (i) main effects due to
each supplement; (ii) comparisons of main effects of dif-
ferent supplements; and (iii) effect modification of one
supplement by another.
Methods/Design
Study design
The current trial has been designed to specifically inves-
tigate the effects of pre-natal and infant nutritional sup-
plementation on infant immune development in rural
Gambia, and has been given the acronym ENID: Early
Nutrition and Immune Development. The ENID trial is
a 2 × 2 × 2 factorial randomized partially blind trial of
nutritional supplementation to pregnant women and
their infants in the West Kiang region of The Gambia.
Within the trial design, women are randomized to
supplementation from when they book for antenatal
care (< 20 weeks gestation) until delivery and then their
infants are further randomized from 6 to 12 months of
age. The primary outcome measurements focus on in-
fant immune development. Recruitment into the ENID
trial started in early 2010, with the first infant born in
August that year. It is anticipated that antenatal recruit-
ment will be completed in December 2012, with the final
infant reaching 12 months of age by approximately
August 2014.
Setting and participants
The ENID Trial is based in the West Kiang region of The
Gambia, a rural subsistence farming community of savannah
and farmland, a roughly 750 km2 rectangular tract of farm-
land bounded on 3 sides by the River Gambia and its tribu-
taries. The trial is based in all 36 villages currently registered
within the West Kiang Demographic Surveillance System
(DSS; total resident population approximately 15,000). Fol-
lowing approval from the local community, all women of
reproductive age (18 to 45 years) are invited to participate,
and informed consent obtained. For the purpose of in-
ormed consent, a trained field worker explains the full
details of the study to the subject, covering all aspects of
the study as laid out in an information sheet. Illiterate
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subjects additionally have the full information sheet
read to them; literate subjects are given time to read
the information sheet in their own time. Any ques-
tions that arise are then answered by the field
worker, or referred to the principal investigator for
clarification. Subjects are also given the possibility to
speak to one of the study investigators (PI, study mid-
wife, study clinician) if they wish. If the subject agrees to
participate, written consent is obtained, through either a
signature or thumb print. Women who are (i) currently
pregnant (beyond 20 weeks on ultrasound assessment), (ii)
currently enrolled in another MRC study, (iii) severely an-
aemic at booking (haemoglobin (Hb) less than 7 g/dL), or
(iv) report the onset of menopause are excluded from entry
into the trial.
Each month from enrolment participating women are
visited by a member of the study team with a short
questionnaire on the date of their last menstrual period
(LMP). When a menses has been missed, a urine sample
is collected for pregnancy testing using hCG tests
(QuickVue™ One-Step hCG Urine Test, bioMérieux,
UK). Women with a positive test are then invited to
MRC Keneba for an ultrasound examination. Women
confirmed as being between 10–20 weeks pregnant by
ultrasound (using a Siemens ACUSON Antares Ultra-
sound Imaging System (Siemens Medical Solutions USA,
Inc., California, USA) with a CH6-2 (5.71 MHz) trans-
ducer), are randomized into the trial, with supplementa-
tion commencing the following week.
The ENID Trial aims to have complete data for 800
mother-infant pairs. To account for losses to follow up
(including those from withdrawals, out-migrations, preg-
nancy losses, infant deaths), ethical approval was obtained
to recruit up to 1000 pregnant women, to allow for a max-
imum attrition rate of 20%. We anticipate, however, that
fewer than 1000 women will need to be recruited, as the
West Kiang population is highly motivated for participa-
tion in research projects.
The trial is approved by the joint Gambia Government /
MRC The Gambia Ethics Committee (Project number
SCC1126v2). The trial is monitored by an Independent
Trial Monitor (ITM; Dr Karen Edmond, London School
of Hygiene and Tropical Medicine) and a Data Safety
Monitor (DSM; Dr Kalifa Bojang, Royal Victoria Teach-
ing Hospital, Banjul, and MRC Unit, The Gambia). The
primary role of the ITM is to monitor adherence to the
trial protocol and to supervise the progress of the trial
toward its objectives. The DSM will conduct interim
analyses of the safety data, by randomization group, per-
taining to the occurrence of Adverse Events (AE); (i)
following recruitment of one half of antenatal cases, (ii)
on completion of antenatal recruitment, and (iii) once
half the infants have reached the final point in the trial,
at 12 months of age. In addition, reports on Serious
Adverse Events (SAE) are submitted to the DSM in real
time. The trial will be stopped in the case of (A) any un-
expected SAE (such as a severe/fatal allergic reaction to
any one of the trial supplements) or (B) a consistent
pattern of SAEs and/or AEs within one or more arms of
the trial, and following the direction of both the DSM
and ITM. No interim analyses on the outcome data are
planned.
Intervention - pregnancy
At booking eligible women are randomized to one of
four intervention arms: 1.) Iron-folate (FeFol), represent-
ing the usual standard of care during pregnancy, as per
Gambian Government guidelines; 2.) Multiple micronu-
trients (MMN), a combination of 15 micronutrients,
specifically designed for use during pregnancy, and as
formulated by UNICEF/WHO/UNU. A single tablet pro-
vides the Recommended Dietary Allowance (RDA) for
each micronutrient. However, in view of evidence to sug-
gest that in this region a daily supplement of twice the
RDA is more effective with regard to birth outcomes
[17], women in this arm of the trial are supplemented at
2 × RDA (but with the same level of iron and folate to the
FeFol arm). Both the FeFol and MMN supplements are
formulated as tablets and manufactured by Scanpharm,
Denmark (www.scanpharm.dk). 3.) Protein-energy and
iron-folate (PE + FeFol), a lipid based nutritional supple-
ment (LNS) providing the same level of iron and folate to
the FeFol only arm, but with the addition of energy,
protein and lipids. 4.) Protein-energy and multiple
micronutrients (PE +MMN), a micronutrient fortified
LNS supplement providing the same level of micro-
nutrients to the MMN arm (including FeFol), in addition
to the energy and protein and lipid content. The two LNS
products are manufactured by Valid Nutrition, Nairobi,
Kenya (www.validinternational.org). The composition of
the four pre-natal supplement groups is as detailed in
Table 1.
Randomization and allocation
Randomization into the trial is in blocks of 8, using
an automated system, with the 8 groups reflecting
the 8 combinations of prenatal and infancy supple-
ments (Figure 1). Once randomized, the code allocated to
each mother will remain the same for her infant. Alloca-
tion of each supplement combination to a number be-
tween 1 and 8 was performed by Dr Mathilde Savy (IRD,
France), with this information passed directly to the sup-
plement manufacturers. Each box of supplement is then
distinguished by a number between 1 and 8. An additional
hard copy of the code assignment is held in the safe in
Keneba, accessible by the field station senior administrator
and only at the request of the trial monitors. The antenatal
arm of the trial is partly open, since it is not be possible to
Moore et al. BMC Pregnancy and Childbirth 2012, 12:107 Page 3 of 8
http://www.biomedcentral.com/1471-2393/12/107
blind the field assistants or the women to the supplement
type (tablet vs. LNS); all other investigators however will
not know to which group the women belong.
Using the automated allocation system, a member of
the data office at MRC Keneba, independent to the trial
analysis, allocates mother-infant pairs to their supple-
ment codes and then generates printed labels for the
supplement pots (including subject ID, name, and date
of supplement period). Four members of the MRC
Keneba field staff working on a different study then label
the supplements using lists, by supplement allocation
number (e.g. Group 1, women a, b, c etc.) provided by
the data office. Supplements are then administered to
the women on a weekly basis by field assistants posted
to the community. Compliance with the supplement is
assessed through the collection of all unused supple-
ments at the end of each week. At these weekly visits, a
record of maternal morbidity is also collected. Random
spot checks to assess used and unused supplements are
additionally performed on 10% of women each week.
Details of any other maternal morbidity requiring med-
ical care will be captured electronically through the
Keneba clinic or, for cases seen at either of the other two
Government Health Centres in West Kiang (Karantaba
and Kwinella), through a ‘Maternal Morbidity’ Form held
by health personnel.
Scheduled pregnancy and delivery measurements and
sample collection details
At 20 and 30 weeks gestation, women attend the MRC
Keneba clinic for a detailed antenatal assessment. At
each visit, the following assessments are made: Standard
antenatal check: including blood pressure; haemoglobin;
urine sample. Women are also offered voluntary coun-
seling and testing (VCT) for HIV, as is routine practice
in West Kiang. Maternal anthropometry: weight; standing
height; sitting height; lower leg length; waist and hip cir-
cumference and mid-upper-arm circumference (MUAC).
All measurements are made using standard, regularly vali-
dated equipment and following the relevant SOP. Venous
blood sample: haematology and plasma micronutrient
Table 1 Nutritional composition of daily intake of
pregnancy supplements
Tablets LNS
FeFol MMN PE + FeFol PE +MMN
Iron (mg) 60 60 60 60
Folate (μg) 400 400 400 400
Vitamin A (RE μg) 1600 2.85 1600
Vitamin D (IU) 400 - 400
Vitamin E (mg) 20 4.2 20
Vitamin C (mg) 140 2.25 140
Vitamin B1 (mg) 2.8 0.3 2.8
Vitamin B2 (mg) 2.8 0.45 2.8
Niacin (mg) 36 1.35 36
Vitamin B6 (mg) 2.8 0.15 2.8
Vitamin B12 (μg) 5.2 0.1 5.2
Zinc (mg) 30 3.3 30
Copper (mg) 4 1.05 4
Selenium (μg) 130 6.15 130
Iodine (μg) 300 2.6 300
Energy (kcal) 746 746
Protein (g) 20.8 20.8
Lipids (g) 52.6 52.6
Data in italics represent MMN content from base ingredients.
Consenting women who 
fall pregnant 
FeFol
N=250 
MMN
N=250 
PE
N=250 
LNS 
N=125 
+MMN 
N=125 
All resident women of 
reproductive age 
Randomization at 6 month of age to MMN fortified weaning food or placebo 
Randomization at booking to pre-natal supplement 
LNS 
N=125 
+MMN 
N=125 
LNS 
N=125 
+MMN 
N=125 
PE+MMN 
N=250 
LNS 
N=125 
+MMN 
N=125 
Figure 1 Trial design.
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status, plus samples of serum, plasma and DNA are
biobanked for future analyses. Fetal ultrasound: Fetal
biometry by ultrasound (Siemens ACUSON, as above),
including bi-parietal diameter, occipital frontal diameter,
head circumference, abdominal circumference and femur
and tibia length.
In this community, the majority of women choose to
deliver in their homes with the support of a Traditional
Birth Attendant (TBA). Through a network of posted
field workers, we attempt to attend all deliveries occur-
ring in West Kiang. Following delivery a sample of cord
blood (15 mL) is collected and the placenta transported
on ice to the MRC Keneba laboratory for processing. On
arrival, cord blood samples are processed and placental
material is collected for the assessment of placental
micronutrient transport proteins.
Within 72 hours of delivery, all women and their new-
born infants are visited by one of the study midwives for
a ‘baby check’, which includes infant anthropometry
(weight, length, MUAC, head circumference), gestational
age assessment by Dubowitz score [18] and a general
health check. Neonates assessed as unwell are referred to
the MRC Keneba clinic for assessment by the study clin-
ician/resident paediatrician.
Intervention - infancy
In The Gambia, exclusive breastfeeding to six months of
age is recommended and the National Nutrition Agency
(NaNA) actively promotes this practice to the popula-
tion. Community-based peer counselling in exclusive
breastfeeding has proven efficacious in improving both
the rate and duration of exclusive breastfeeding [19,20].
Within the ENID Trial, we will work with NaNA to train
community health nurses to promote exclusive breast-
feeding for all participating women. The purpose of this
element of the study is to ensure that all women are pro-
vided with the knowledge to provide optimal nutrition
to their infants during the period from birth to 6 months
of age.
Between birth and six months of age, infants are vis-
ited weekly for the collection of morbidity data by ques-
tionnaire. From six months of age, infants commence
supplementation with either an unfortified LNS paste or
the same LNS formulation fortified with multiple micro-
nutrients. The nutritional composition of both products
is as detailed in Table 2. This arm of the trial is double
blind, with infants receiving identically packaged formu-
lations prepared in individually labeled plastic contain-
ers. Supplements are distributed to mothers on a weekly
basis, and the mother is asked to administer the supple-
ment/placebo on a daily basis by mixing 20 g of the LNS
product with the infant’s normal weaning food. Identical
spoons are provided to mothers, to encourage that a uni-
form amount is given to each infant, per day. Mothers are
asked to give the study infant the full dose, and compli-
ance is assessed through random spot checks and by a
questionnaire administered on a weekly basis. At these
weekly visits, a morbidity questionnaire is also completed
for each infant.
Scheduled infancy measurements and sample
collection details
Following delivery, infants are seen at the MRC Keneba
field station when they are 1, 8, 12, 24 and 52 weeks of
age, with additional home visits at 16, 20, 32 and 40 weeks
of age. Table 3 details the data and sample collection sched-
ule for each visit. At all time points, detailed measures of
infant anthropometry are taken using standard protocols
with regularly validated equipment. Measurements include
weight, length, knee-heel length, head circumference, ab-
dominal circumference, chest circumference, thigh circum-
ference, MUAC, and triceps, biceps, subscapular, suprailiac
and thigh skinfold thickness. At all visits in Keneba, a 5 mL
sample of breast milk is also collected from each breast, for
Table 2 Nutritional composition of 20 g of weaning food
fortificant
Nutrient PE PE +MMN
β-Carotene (μg RE) 1.84 400
Vitamin C (mg) 1.88 30
Folic acid (μg) 13.1 80
Thiamine (mg) 0.06 0.3
Riboflavin (mg) 0.04 0.4
Vitamin B3 (mg) 0.32 4
Pantothenic acid (mg) 0.08 1.8
Vitamin B6 (mg) 0.02 0.3
Vitamin B12 (μg) 0.06 0.5
Vitamin D (μg) 0.34 5
Vitamin E (mg) 0.12 2.7
Vitamin K (μg) 1.40 10
Iron (mg) 0.46 9
Zinc (mg) 0.24 4
Calcium (mg) 33.1 100
Potassium (mg) 91.76 152
Copper (mg) 0.02 0.2
Selenium (μg) 1.44 10
Iodine (μg) 1.40 90
Phosphorus (mg) 42.56 82
Magnesium (mg) 14.56 16
Manganese (mg) 0.08 0.08
Total energy (kcal) 108 108
Linoleic acid (g) 1.29 1.29
Linolenic acid (g) 0.29 0.29
Data in italics represent MMN content from base ingredients.
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the assessment of breast milk micronutrient levels and
residual samples frozen at −80°C for long term storage.
Milestones of Gross Motor Development are assessed
monthly, from when the child is six months of age [21].
At 12 months of age, parental anthropometry is taken and
a socio-economic questionnaire completed.
Study personnel administer EPI vaccines to all infants,
as per Gambian government protocol (Table 4). All
study vaccines are acquired direct from the EPI Depart-
ment of the Gambia Government, and the cold-chain
managed thereafter by the study team. At 12, 24 and
52 weeks of age, a venous blood sample is collected from
infants for the assessment of antibody response to vac-
cination, micronutrient status, with residual aliquots bio-
banked for further biomarker measurements. Cord blood
and samples from 12 and 24 week bleeds will be used to
assess anti-diphtheria, tetanus toxoid, Haemophilus B
Influenzae, OPV and Hepatitis B antibody titres will be
measured. In cord, 24 week and 52 week samples, measles
antibody levels will be assessed. DNA samples for both
mother and infant are collected and held within the
Keneba Biobank.
Thymus size is assessed sonographically at 1, 8, 24 and
52 weeks using a validated method in which the trans-
verse diameter of the thymus and the saggital area of its
largest lobe are multiplied to give a volume-related
thymic index (TI) [22]. The human thymus is a primary
lymphoid organ essential for the establishment of a nor-
mal peripheral T-lymphocyte immune system. Whilst lit-
tle data exists to support TI as a robust measure of
immunocompetence, TI has been shown to correlate
with thymus weight at autopsy and has been used previ-
ously by our group both in Keneba and in Bangladesh to
show that the human thymus is sensitive to environmen-
tal influences during infancy [8]. Thymus size will be
measured using a Siemens Acuson ultrasound unit to-
gether with a P10-4 Transducer (Siemens, UK). To fur-
ther validate the significance of TI and to understand
the cellular basis of any observed alterations in antibody
response, we will measure cellular markers of immunity
in a sub-sample of the cohort (one full calendar year of
births), using samples of infant blood collected at 12, 24
and 52 weeks of age.
Study outcomes
The primary outcome measure for this study is TI. As
with previous datasets on thymic development [9] we
will assess the impact of the interventions on TI at the
different time points (week 1, 8, 24 & 52) separately, and
on the time points pooled. These separate analyses are
deemed necessary, since the different time points reflect
different exposures (week 1 measurements reflecting
prenatal supplementation only, week 52 reflecting com-
bined pre- and post-natal interventions). Secondary out-
comes include (i) antibody response to vaccination and
(ii) detailed cellular immunology (on a subset of infants
only).
Analytical plan
The ENID Trial aims to have complete data on a total of
800 mother-infant pairs. There are three types of ques-
tions that the proposed study will address:
(i) Main effects due to each supplement (i.e.
supplement vs. placebo (usual care; FeFol only)).
(ii) Comparison of main effects of different
supplements (i.e. supplement A vs. supplement B).
(iii) Effect modification of one supplement by another.
In each case we consider analysis of both (a) the full
data set (i.e. all combinations of treatment A, B & C;
subgroups 1–8 in Table 5) and and (b) also (in order to
avoid possible interference from interactions) in the sub-
set of subjects who did not receive any supplements
Table 3 Data and sample collection schedule during infancy
Measure Infant age (weeks)
1 4 8 12 16 20 24 28 32 36 40 44 48 52
Thymic Index + + + +
EPI Vaccination + + + + +
Venous Bleed + + +
Anthropometry + + + + + + + + +
Breast milk + + + + +
Table 4 EPI vaccine schedule, birth to 12 months – The
Gambia
Age (wk) Vaccine
0 (within 72 hours of birth) BCG, HBV, OPV
8 Penta, OPV, Pneumo
12 Penta, OPV, Pneumo
16 Penta, OPV, Pneumo
40 Measles, Yellow Fever, OPV
BCG – Bacillus Calmette-Guérin; HBV – Hepatitis B Vaccine; OPV – Oral Polio
Vaccine; Penta – Combined DPT (diphtheria, pertussis, tetanus), HBV and
Haemophilus influenzae Type B (Hib).
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other than that/those involved in the particular hypoth-
esis under test.
(a) When considering questions (i) and (ii) analyzing
the full dataset we fit the model:
Yi ¼ β0 þ βAAi þ βBBi þ βCCi þ εi
For question (i) we will test the significance of βA,
βB and βC; for question (ii) we examine the
contrasts βA-βB, βA-βC and βB-βC.
When employing the full data set to consider the
first order interactions between two treatments –
question (iii) –we would fit the model including all
these interactions:
Yi ¼ β0 þ βAAi þ βBBi þ βCCi þ βABAiBi
þ βACAiC þ βBCBiCi þ εi:
We would then test the significance of βAB, βAC and
βBC. For completeness we would also fit the second
order interaction between A, B & C using the model
below, although the study is not powered for that.
Yi ¼ β0 þ βAAi þ βBBi þ βCCi þ βABAiBi
þ βACAiC þ βBCBiCi þ βABCAiBiCi þ εi:
(b) The subset of data used to fit the main effect of
treatment A (say) would include only subgroups 1
and 2 and fit the model:
Yi ¼ β0 þ βAAi þ εi:
To compare treatment A with B excluding
interference from C we would use subgroups 1–3
and 5 and fit the model:
Yi ¼ β0 þ βAAi þ βBBi þ εi
Finally, to examine the interaction between
treatment A and B excluding interference from C
we would employ the same subgroups (1–3 & 5)
and fit the model:
Yi ¼ β0 þ βAAi þ βBBi þ βABAiBi þ εi:
The primary outcome measurement (thymic index, TI)
will be made on infants of different sizes and ages. We
will therefore carry out the analysis on the logarithm of
the TI measurements since the (a) percentage changes
are more appropriate, (b) the standard deviation is then
essentially independent of the mean and (c) the residual
distribution is more symmetrical. Otherwise the analysis
will be based on least-squares regression controlling for
infant size and season of observation and other covari-
ates that have a noticeable effect on the variance.
Since three treatments or three pairs of treatments are
under consideration for each of the above questions we
have applied a Bonferroni correction for the best of
three tests.
Table 6 gives the required numbers to achieve a power
of 80% with significance level of 5%. The different col-
umns correspond to the different questions listed above.
The effect sizes considered are similar to those previ-
ously observed between seasons [8]. We also assume
that between individuals the sd[log(TI)] = 0.21, which is
the standard deviation of the residuals after controlling
for infant size and season of observation derived from
Collinson et al’s data [8].
Discussion
The ENID Trial has been designed to investigate the im-
pact of combined pre- and post-natal nutritional supple-
mentation on immune development in Gambian infants.
The trial design will specifically allow us to establish which
combination of supplements is most effective and also the
most critical periods of intervention in pregnancy and
Table 5 Treatment combinations
Subgroup Treatment
A B C
1 0 0 0
2 1 0 0
3 0 1 0
4 0 0 1
5 1 1 0
6 1 0 1
7 0 1 1
8 1 1 1
Table 6 Sample size required for a range of effect sizes and different hypotheses to be tested
(i) Main effects of treatments
versus placebo
(ii) Comparison of pairs of main
effects versus one another
(iii) Interactions between pairs of
treatments
Effect size (% difference in TI) Full dataset Reduced dataset* Full dataset Reduced dataset* Full dataset Reduced dataset*
5% 847 3388 1694 3388 3388 6776
7.5% 385 1542 771 1542 1542 3084
10% 222 888 444 888 888 1776
* Avoiding interference from irrelevant treatment.
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infancy, and whether any observed effects are additive. To
date, there are no previous registered or published trials
on this topic. Previous trials of MMN [23] and PE [24]
interventions in pregnancy have concentrated almost ex-
clusively on birth weight and perinatal survival as out-
comes. A single trial (in HIV-infected mothers) has
investigated a limited range of T-cell subsets in pregnancy,
but not in the offspring, and found that limited MMN
supplementation (vitamins B, C and E), but not vitamin A
alone, increased CD4+ and CD8+ counts [25]. The ENID
Trial will also provide valuable data on other important
developmental markers including growth.
Where there is evidence of benefit from a specific
intervention/combination of interventions, future re-
search should focus on refining the supplements to
achieve the optimal, most cost-effective balance of inter-
ventions for improved health outcomes. Findings may
also precipitate a separately funded larger or multi-
centre trial with morbidity and/or mortality as the pri-
mary outcome. Where evidence indicates a defect in a
specific component/components of immune function,
more detailed interrogation within a subset of subjects
from follow-up trials, likely to involve more intense sam-
ple collection schedules, will be justified, and will help to
further our understanding of specific interactions. In the
event that none of the supplementation combinations
under trial have a marked impact on immune develop-
ment across the whole cohort, data obtained may help
pinpoint specific vulnerable groups (such as women with
low pre-pregnancy BMI’s for whom intervention may be
most efficacious), for further targeted research.
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